Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Is the Phoenix Sign Phenomenon Due to Vasodilation? a Double-Blinded, Randomized Controlled Trial Comparing Motor Function Recovery After Diagnostic Common Fibular Nerve Block with Lidocaine and Papaverine

NCT06637046 is registered in ClinicalTrials.gov with Stephen Barrett as lead sponsor.

NCT NCT06637046
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06637046 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Is the Phoenix Sign Phenomenon Due to Vasodilation? a Double-Blinded, Randomized Controlled Trial Comparing Motor Function Recovery After Diagnostic Common Fibular Nerve Block with Lidocaine and Papaverine
Lead sponsor
Stephen Barrett
Phase
Not applicable
Overall status
Completed
Start date
March 15, 2020
Completion date
November 1, 2023
Enrollment
20 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

drop foot